Healthcare

The study is a pivotal, double-blind, placebo-controlled Phase 3 trial in Indonesia evaluating the efficacy and safety of R327G in diabetic foot infections. Currently, 90 patients are enrolled at an enrolment rate of about 4.5 patients per week. Patient recruitment and dosing remain ongoing …

Following the transaction, Starpharma holds 66% of Petalion and Medicxi holds 30%. Medicxi keeps board representation and an active strategic role. Petalion becomes a UK-incorporated subsidiary of Starpharma Holdings Limited. Under the revised structure, Starpharma leads operations and supplies its DEP dendrimer platform, conjugation …

Argenica Therapeutics Limited (ASX:AGN), a Perth-based clinical-stage biotechnology company, reported laboratory results on xaranetide, its lead drug candidate. In cell-line experiments, the compound inhibited three types of ion channel linked to brain injury: a subtype of the NMDA receptor, CaV2.2 and ASIC1a. Argenica said …

EBR Systems, Inc. (ASX:EBR) announced on 20 October 2026 that it has formally submitted an application to Australia's Therapeutic Goods Administration (TGA) for inclusion of its WiSE System on the Australian Register of Therapeutic Goods, known as the ARTG. The Santa Clara, California-based company …

Pro Medicus (ASX:PME) develops Visage medical imaging software used by hospitals and imaging groups, mainly in the United States. On 19 October 2026, the shares closed at $177.64, up approximately 1.09%. Over the longer term, the shares are down approximately 38.07% over the past …

ResMed Inc. (ASX:RMD) supplies devices and software for sleep apnoea and respiratory care, and is listed on both the NYSE and the ASX. On 19 October 2026, the shares closed at $34.07, down approximately 0.82%. Over the longer term, the shares are down approximately …

Sigma Healthcare (ASX:SIG) is a pharmacy wholesaler, retailer and franchisor that merged with the Chemist Warehouse Group. On 19 October 2026, the stock finished the session at $2.83, down approximately 0.70%. Over the longer term, the shares are down approximately 4.71% over the past …